About Ankyrin repeat domain-containing protein 60
Ankyrin repeat domain-containing protein 60 (ANKRD60) is a protein
from Homo sapiens identified by UniProt accession
Q9BZ19, 345 residues long.
MolForge cross-references it against 0 known binders and
20 disease associations.
Target properties
| Protein name | Ankyrin repeat domain-containing protein 60 |
| UniProt accession | Q9BZ19 |
| Gene | ANKRD60 |
| Organism | Homo sapiens |
| Length | 345 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (20)
Diseases linked to this target (Open Targets).
- adolescent idiopathic scoliosis · score 0.20
- alkaline phosphatase measurement · score 0.09
- heel bone mineral density · score 0.07
- pancreatic carcinoma · score 0.06
- PHF-tau measurement · score 0.06
- appendicular lean mass · score 0.05
- 22q11.2 deletion syndrome · score 0.05
- mathematical ability · score 0.04
- age-related macular degeneration · score 0.04
- wet macular degeneration · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BZ19-F1 | alphafold | PREDICTED | 72.90 | — |
Amino-acid sequence (345 residues)
MTRGRAWGMR RAAAGAGGAR AAGPTGGASR LHPNAGRRSG ARAGAQGCGG PRVGSADSRA LPAQPLACAR GRSQRLVCDP KAASALPDLA PDVFVLRVRL EETGEMFRVA NCRGDMTVRE LKEELDLMVG IPFNLQRLQY LDEGVLMDDT TLKFHDVVPG GIISLCIWHH DGWTELVLAA VEGDPSKLSC LGLTEDSFYR TANSEHFEGE KWKHWTSQRA FVALYVASHR GHFDAVQYLL EHGASCLSRS PLGRTPLHVA AAMGRSDCII LLLQHGASIH DRDAKGETPI SIAHRLNHTL SERQMVLLHR IAKSGIRDLN DLVMKNALQR VKSGFRSEKM TMTPH
Explore Ankyrin repeat domain-containing protein 60 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets